ArticleMediators of inflammation2026
LY294002 and LiCl Mitigate Neonatal ExPEC Meningitis Through Akt/GSK3β Signaling Modulation.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HOXC9 promotes cell proliferation and suppresses mitochondria-dependent apoptosis through the AKT/mTOR pathway in esophageal squamous cell carcinoma.Molecular and cellular biochemistry · 2026Article
- LY294002 and LiCl Mitigate Neonatal ExPEC Meningitis Through Akt/GSK3β Signaling Modulation.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNeonatal purulent meningitis (NPM) is a life-threatening condition associated with high mortality rates and a substantial risk of severe long-term neurological sequelae among survivors. Extraintestinal pathogenic Escherichia coli (ExPEC) is the predominant causative agent of NPM and exhibits multidrug resistance. Targeting host signaling pathways is a promising therapeutic approach. In this study, we aimed to evaluate the therapeutic potential of LY294002 (a PI3K/Akt inhibitor) and lithium chloride (LiCl) (a GSK3β inhibitor) in a neonatal mouse model of ExPEC meningitis.
methodsNeonatal mice were infected with clinical ExPEC isolates to induce meningitis. LY294002 or LiCl was administered as an intervention. Brain bacterial load was quantified via culture, while inflammation was assessed using RT-qPCR to evaluate the expression of inflammatory cytokines; hematoxylin-eosin (HE) staining was also performed. The expression and localization of tight junction (TJ) proteins were analyzed using immunohistochemistry, and western blotting was used to quantify TJ proteins and key signaling molecules, including Akt, phosphorylated Akt (p-Akt Ser473), GSK3β, and phosphorylated GSK3β (p-GSK3β Ser9).
resultsExPEC colonization in the brain tissue was confirmed via bacterial culture. Early intervention with LiCl significantly reduced bacterial load. HE staining revealed meningeal thickening in infected mice, which was alleviated by both LY294002 and LiCl treatments. Western blotting and immunohistochemistry consistently demonstrated a marked reduction in the expression of TJ proteins following ExPEC infection, and their levels were substantially restored by both the interventions. These protective effects were associated with the modulation of the Akt/GSK3β signaling pathway.
conclusionLY294002 and LiCl reduced neuroinflammation and preserved the blood-brain barrier (BBB) integrity in the neonatal ExPEC meningitis model, likely via modulation of the Akt/GSK3β pathway. These results underscore the potential of this pathway as a therapeutic target and provide a basis for further preclinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.